Precision approach to population health can benefit patients and health systems
The European Federation of Pharmaceutical Industries and Associations (EFPIA), in collaboration with the EFPIA Oncology Platform (EOP), commissioned a report...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Strategy in rare disease requires specialist expertise and understanding. CRA understands the unique challenges that rare disease companies face, and we implement a distinctive approach to help drive their success.
CRA’s experience stems from hundreds of rare disease engagements across many therapeutic areas.
Healthcare Claims Analytics Platform (HCAP) is a modular, dynamic, rapidly updating data-visualization tool that provides streamlined analysis of patient, Health Care Practitioner (HCP), and Health Care Organization (HCO) level data to support decision making and insight generation. HCAP supports clients in visualizing advanced analytics to provide intelligence on patients, physicians, hospitals, and the broader healthcare market. With the information obtained from HCAP, clients are better informed to make key strategic decisions.
The European Federation of Pharmaceutical Industries and Associations (EFPIA), in collaboration with the EFPIA Oncology Platform (EOP), commissioned a report...
Despite a large number of people globally being affected by rare kidney diseases, research support and health care policy programs usually focus on the...
Milan Ferguson presents during the panel session titled ” The value of newborn screening: An SMA case study.” For more information on this event, click here.
CRA is a proud sponsor of the congress. Cecile Matthews and Bhavesh Patel present their session titled “Project LEOPARD (Long-term Evolution & Outlook for...